Bone Grafts Research - Spine Fusion, Surgery, Procedure, Risks

Bone Grafts Research Today is a free monthly online journal that collates and summarizes the latest research about Bone Grafts, including details on spine fusion, surgery, procedure, risks.


Bone Grafts Research Today

Home

View Latest Issue

Information About Bone Grafts

Books on Bone Grafts

Advertising in Research Today

View Other Research Today Publications



Splenocytes can replace chimeric cells and maintain allograft tolerance.

Hayashi Y, Yamazaki S, Kanamoto A, Takayama T

Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan.

BACKGROUND: The induction of donor-specific tolerance (DST) has recently attracted widespread attention as a new approach to facilitate engraftment without using immunosuppressants. One way in which to induce DST is to establish a chimeric state that allows donor-derived cells to exist within a recipient. This study aims to investigate whether splenocytes can be used to maintain chimerism and to prolong graft survival. METHODS: Mixed bone marrow (BM) was established in this chimeric model by lethally irradiating C3H mice on day 0, and transplanting BM from C3H and B6D2F1 mice into them. Skin grafts from C57BL/6 mice were transplanted on day 30. On day 60, splenocytes from C3H (group A), B6D2F1 (group B) and B6C3F1 (group C) mice were administered to the chimeric mice. The class I major histocompatibility complex (MHC) type, the percentage of chimeric cells in the peripheral blood, and the survival of skin grafts were assessed. RESULTS: After splenocyte infusion, BM-derived chimeric cells were eliminated from the periphery in group A (86.2+/-5.9% to 0.04+/-0.03%, P=0.0008), B6D2F1-derived cells increased in quantity and established an allochimera in group B (83.7+/-7.2% to 99.6+/-0.2%, P=0.021), and in group C the B6C3F1-derived cells significantly increased to a level of 77.8% at 180 days after infusion (P=0.014), thereby maintaining the new chimerism. Skin grafts in groups B and C survived for at least 200 days (P=0.0003 and P=0.0001, respectively). CONCLUSIONS: Chimerism arising from cells with a partial MHC match to the graft allows the maintenance of specific immunotolerance and graft survival.

Published 13 November 2007 in Transplantation, 84(9): 1168-73.
Full-text of this article is available online (may require subscription).

Place a permanent text-link or advertisement here for just US$15.

© 2004-2008 Bone Grafts Research Today. All Rights Reserved.



Bone Grafts Research Today Archive:

Volume 1 (2004)
  Issue 1 (September)
  Issue 2 (October)
  Issue 3 (November)
  Issue 4 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)



Bone Grafts Books

Graft vs. Host Disease, Third Edition

Graft vs. Host Disease, Third Edition